Información del producto
- 6-cyano-4-(N-ethylsulfonyl-N-methylamino)-3-hydroxy-2,2-dimethylchromane
- Chromanol 239B
- Ethanesulfonamide, N-(6-cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl)-N-methyl-, trans-
- Ethanesulfonamide, N-[(3R,4S)-6-cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl]-N-methyl-, rel-
- N-(6-cyano-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-chromen-4-yl)-N-methylethanesulfonamide
- N-[(3R,4R)-6-cyano-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-chromen-4-yl]-N-methylethanesulfonamide
- N-[(3R,4S)-6-cyano-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-chromen-4-yl]-N-methylethanesulfonamide
- Trans-N-[6-Cyano-3,4-Dihydro-3-Hydroxy-2,2-Dimethyl-2H-1-Benzopyran-4-Yl]-N-Methyl-Ethanesulfonamide
- rel-N-[(3R,4S)-6-Cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl]-N-methylethanesulfonamide
Chromagnol is a drug that inhibits the enzyme protein kinase C (PKC). It has been shown to have inhibitory properties on cardiac muscle cells and whole-cell recordings of heart cells. Chromagnol has also been shown to affect the function of bowel disease, including papillary muscle. Chromagnol has been shown to have effects on cardiac and atrial tissue. This drug may be a potential treatment for autoimmune diseases, such as multiple sclerosis, or other diseases that are caused by PKC overactivity. The mechanisms of action are not fully understood but it is believed that chromanol binds to the cytosolic Ca2+ ion channel, preventing it from opening and releasing Ca2+, which leads to an increase in intracellular Ca2+.
Propiedades químicas
Consulta técnica sobre: 3D-FC166930 Chromagnol
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.